Skip to main content

RA-PROPR

A Real-World Comparative Effectiveness Trial of Treatment Strategies in Patients with Rheumatoid Arthritis

medical-cross
Rheumatoid arthritis
user
All genders
person-wave 18+
world
Recruiting now
More information  

Overview

Principal Investigator: Timothy E. McAlindon, MD, MPH

The purpose of the study is to assess whether the addition of a TNFi-biologic (tumor necrosis factor inhibitor) medication to methotrexate (MTX) is superior to adding a targeted synthetic DMARD (disease-modifying anti-rheumatic) medication to MTX for people with active RA despite current MTX treatment.

Contact Us

user
Sarah Pilgrim, Study Coordinator

Study details

Inclusion Criteria
  • Patients with active, disabling RA despite the use of methotrexate ≥3 months
  • If receiving glucocorticoids or NSAIDs, on stable doses for ≥2 weeks
  • Insurance plan allows access to at least 1 drug in each of the two treatment strategies, TNFi-biologic vs. tsDMARD
Exclusion Criteria
  • Use of leflunomide, sulfasalazine, cyclosporine, or azathioprine within 2 months
  • Prior treatment with a TNFi-biologic, non-TNFi biologic, or targeted synthetic DMARD
  • History of HIV
Study Requirements

This study involves up to 6 regularly scheduled clinic visits to Tufts over the course of 12 months. We will collect information about symptoms. At each visit, blood (about 2 teaspoons) and a urine sample will be collected. Patients will receive compensation for their time for study participation, $60 at the baseline visit and $50 for each subsequent visit.

Jump back to top